Novo Nordisk A/S
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NONOF research report →
Companywww.novonordisk.com
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases.
- CEO
- Maziar Mike Doustdar
- IPO
- 2010
- Employees
- 77,406
- HQ
- Bagsvaerd, DK
Price Chart
Valuation
- Market Cap
- $196.58B
- P/E
- 10.51
- P/S
- 3.91
- P/B
- 6.31
- EV/EBITDA
- 7.65
- Div Yield
- 4.06%
Profitability
- Gross Margin
- 81.85%
- Op Margin
- 45.30%
- Net Margin
- 37.20%
- ROE
- 66.36%
- ROIC
- 32.20%
Growth & Income
- Revenue
- $308.36B · 6.18%
- Net Income
- $102.20B · 1.20%
- EPS
- $23.00 · 1.41%
- Op Income
- $134.71B
- FCF YoY
- -15.55%
Performance & Tape
- 52W High
- $82.50
- 52W Low
- $34.00
- 50D MA
- $39.78
- 200D MA
- $48.98
- Beta
- 0.35
- Avg Volume
- 196.94K
Get TickerSpark's AI analysis on NONOF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our NONOF Coverage
We haven't published any research on NONOF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NONOF Report →